Earth Science Tech, Inc.

What they do

ETST operates a vertically integrated health and wellness platform combining compounding pharmacy operations, telemedicine, clinical support and direct-to-patient fulfillment. Its pharmacies, RxCompoundStore.com in Miami and Mister Meds in Abilene, Texas, compound sterile and non-sterile medications dispensed on patient-specific prescriptions. Telehealth brands Peaks Curative and DOConsultation.com generate referrals and virtual consults that are filled by those pharmacies. Supporting operations include Avenvi (real estate and asset management, which also manages the share repurchase program), Las Villas Health Care, and 80%-owned MagneChef, a direct-to-consumer kitchen products brand.

Revenue drivers

• Compounding pharmacy operations — RxCompound (Miami, licensed in multiple U.S. states and Puerto Rico) and Mister Meds (Texas, fully licensed March 2025 with sterile and hazardous drug handling) generate prescription revenue under Section 503A; this is the core of the business, as revenue rose from $12.0M in fiscal 2024 to $33.1M in 2025 and $35.7M in 2026.
• Telehealth and virtual care — Peaks Curative provides asynchronous consultations and DOConsultation.com offers home-based therapy telehealth; both funnel prescriptions to the Company's own pharmacies, capturing more of the patient journey.
• Real estate and asset management — Avenvi provides physical infrastructure for pharmacy operations and handles ETST's real estate investment activities, including dividend income and realized gains on investments reported in the latest quarter.
• MagneChef consumer products — An 80%-owned direct-to-consumer brand using proprietary IP for kitchen products, described as a diversified revenue stream; the Company says it is expanding the product line.

Recent performance

For the three months ended June 30, 2026, revenue was $9,025,779, up 3% from $8,760,190 a year earlier, with cost of goods sold up 3% to $2,750,510 and gross margin stable near 70%. Net income rose 57% to $715,697, and diluted EPS was $0.003 versus $0.001; total operating expenses fell 3% to $5,697,468, helped by a 15% drop in salaries expense to $3,217,201. Net cash provided by operating activities was $707,131, up 108% from $339,376. The Company repurchased and retired over 3.7 million shares in the quarter versus 505,000 a year earlier.

Strategy

ETST says it is building a vertically integrated healthcare platform that links consultation to fulfillment through its own pharmacies, telehealth brands and fulfillment operations. Management emphasizes non-dilutive financing and capital discipline, noting no final share issuance since October 2023, a reduction in authorized common stock from 750 million to 300 million, an ongoing $10 million share repurchase program, and insider ownership of roughly 48% of outstanding shares. The Company states it has expanded state licensure to a near-national footprint and is evaluating strategic opportunities to broaden telehealth and pharmacy fulfillment into complementary verticals. Balance-sheet priorities include managing the real estate and asset management arm, Avenvi, to support pharmacy infrastructure.

Risks

• Quarterly and annual results may fluctuate — The 10-K states results of operations and key metrics may fluctuate period to period and cause the Company to miss analyst or investor expectations.
• Dependence on expanding offerings — The 10-K warns that failure to expand the number and type of products and services, the number and quality of healthcare providers, and the conditions treated on its platform could materially harm results.
• Customer acquisition and retention — The 10-K cites inability to market to new customers and retain existing ones, or evolving privacy and healthcare laws limiting marketing, as risks to results.
• Competition from larger, established players — The 10-K states ETST operates in highly competitive markets against large healthcare providers and traditional retailers and pharmaceutical providers with significant resources.

Outlook

Management describes fiscal 2026 as the foundation for the current year and says it is focused on scaling by expanding geographic footprint and advancing telehealth and pharmacy fulfillment platforms. The earnings release says all key operating subsidiaries were profitable in the quarter, a trend it says continues from fiscal 2026 and diversifies earnings beyond any single pharmacy. The Annual Meeting of Shareholders was scheduled for August 31, 2026 to vote on proposals including cancellation of the Series B Preferred Stock and to discuss a potential near-term exchange uplisting.